About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Motesanib Does Not Make a Mark in NSCLC Study

by Savitha C Muppala on April 1, 2011 at 8:07 PM
Font : A-A+

 Motesanib Does Not Make a Mark in NSCLC Study

Motesanib, a drug meant for those cancers which are difficult to treat , has unfortunately not lived up to expectations in the phase III trial.

 Infact, it did not make any significant contribution in improving the survival rate among victims of non-small cell lung cancer (NSCLC).

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Blood - Sugar Chart Color Blindness Calculator How to Reduce School Bag Weight - Simple Tips Diaphragmatic Hernia Post-Nasal Drip Loram (2 mg) (Lorazepam) Sanatogen Hearing Loss Calculator Selfie Addiction Calculator Pregnancy Confirmation Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Motesanib Does Not Make a Mark in NSCLC Study Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests